Moderna与默沙东黑色素瘤三期试验达成主要终点
Moderna与默沙东黑色素瘤三期试验达成主要终点
Conclusion: Moderna has already announced that its Phase 3 melanoma trial met its recurrence-free and distant-metastasis-free survival endpoints, but the detailed results are still ahead. For investors, the key question at ESMO is how large and durable the benefit is—not simply whether the study was positive. The presentation could support a further re-rating if the effect is compelling and safety is manageable; because the stock has already repriced sharply, merely confirming the headline may also prompt a “sell-the-news” response.
Data as of 18 October 2026. The latest available US-market close is Friday, 16 October.
What Moderna and Merck have disclosed
-
Phase 3 INTerpath-001 met its primary and key secondary endpoints. The companies said the combination of intismeran autogene (V940/mRNA-4157) and pembrolizumab (Keytruda) significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus Keytruda alone in patients with completely resected stage IIB–IV melanoma. The interim announcement described the results as clinically meaningful, but did not disclose the hazard ratios, confidence intervals, absolute event rates or detailed subgroup results. It also said follow-up will continue for overall survival (OS). Merck/Moderna Phase 3 topline announcement, 19 August 2026
-
The detailed Phase 3 readout is scheduled for ESMO. Merck’s announcement says INTerpath-001 will be presented as a Presidential Symposium at the ESMO Congress in Madrid, running 23–27 October 2026. So as of this report’s date, the detailed Phase 3 results have not yet been publicly presented. Merck’s ESMO 2026 announcement, 13 October 2026
-
The earlier Phase 2b results provide supportive, but not definitive, context. In the smaller KEYNOTE-942 study—157 patients with resected high-risk stage III/IV melanoma—the five-year analysis reported an RFS hazard ratio of 0.51 and a DMFS hazard ratio of 0.411 for the combination versus Keytruda alone. The exploratory OS result was less conclusive: 14 deaths were reported for that analysis, and its confidence interval crossed 1. The Phase 2b study was open-label and much smaller than the pivotal Phase 3 trial, so investors will look for the larger trial to establish the magnitude and consistency of benefit. Detailed five-year results, presented at ASCO on 1 June 2026
-
The disclosed Phase 2 safety profile was broadly consistent with earlier reporting. The most common events attributed to intismeran plus Keytruda were fatigue and injection-site pain, each reported in 59.6%, and chills in 51.0%; the companies reported no Grade 4–5 events attributed to intismeran in that analysis. The Phase 3 topline release said there were no new safety signals, but did not provide detailed Phase 3 event rates. The full safety tables will therefore matter, especially serious or Grade 3+ events, treatment discontinuations, and whether adding the vaccine materially increases burden over Keytruda alone. Five-year results; Phase 3 topline announcement
What in the full results could matter most to investors
-
Effect size and absolute benefit. The hazard ratios and confidence intervals for RFS and DMFS will show how strong and statistically robust the result is. Kaplan–Meier recurrence and distant-metastasis rates at clinically relevant time points, event counts and follow-up maturity will help investors judge the absolute benefit—not just the relative risk reduction.
-
Whether benefit is broad or concentrated. Results by disease stage and other key patient characteristics can indicate how widely the finding may apply. A consistent effect across relevant groups would be more persuasive than a result driven mainly by a narrower subset.
-
Overall survival—and how much remains unknown. OS was not included in the Phase 3 topline result; the companies said patients would continue to be followed. A positive RFS/DMFS result can be valuable without mature OS data, but investors may discount the evidence if survival remains immature or uncertain.
-
Safety and treatment burden. The detailed comparison with Keytruda alone should clarify whether the additional vaccine causes meaningful extra toxicity, treatment stops or other practical burdens. That affects both the clinical case and the prospects for adoption.
-
Practical delivery and commercial path. Intismeran is individualized using mutations from a patient’s tumor. Beyond efficacy, investors will care about the regulatory path and whether personalized manufacture and delivery can work reliably at scale. The trial result itself does not establish approval, uptake or revenue.
Possible stock implications
Moderna shares closed at $218.01 on 16 October 2026. On the Phase 3 topline announcement day, the dividend-adjusted close rose from $62.96 on 18 August to $174.38 on 19 August—+177.0% close-to-close. From the 19 August close to 16 October, the stock was up a further 25.0%. Those are price moves, not a measure of how much of the upcoming detailed readout is already reflected in the share price; other factors can also affect the stock. ; Driven historical prices, 18 August–16 October; announcement-day close-to-close calculation; post-announcement period calculation. Reuters also reported a sharp Moderna share surge following the August topline announcement. Reuters, 19 August 2026
Upside case: detailed results show a clear, durable RFS/DMFS advantage with persuasive absolute differences, a reasonably consistent effect across patient groups, and no material safety penalty. That would strengthen the case that this is a meaningful new cancer-treatment platform and could support further investor revaluation.
Downside or muted-reaction case: the effect is smaller or less consistent than investors expect, the absolute benefit is modest, safety or delivery looks burdensome, or OS remains too immature to add confidence. Even a statistically positive presentation could disappoint if it mostly confirms what the August announcement and subsequent stock move led investors to anticipate. The near-term reaction is therefore likely to depend on the detail and surprise in the data, not just the endpoint headlines.
Sources relied on
- Merck/Moderna, Phase 3 INTerpath-001 topline announcement, 19 August 2026
- Merck, ESMO 2026 presentation announcement, 13 October 2026
- Merck/Moderna, five-year KEYNOTE-942 results presented at ASCO, 1 June 2026
- Reuters, market reaction to Phase 3 topline announcement, 19 August 2026
- Driven structured quote and historical price data for MRNA, through 16 October 2026.